<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308750</url>
  </required_header>
  <id_info>
    <org_study_id>10651</org_study_id>
    <secondary_id>H6Q-US-S004</secondary_id>
    <nct_id>NCT00308750</nct_id>
  </id_info>
  <brief_title>First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanced Stage Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine:&#xD;
&#xD;
      The safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or&#xD;
      docetaxel with carboplatin and any side effects that might be associated with the combination&#xD;
      of these drugs.&#xD;
&#xD;
      Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and&#xD;
      carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer,&#xD;
      compared with the combination of docetaxel and carboplatin.&#xD;
&#xD;
      Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and&#xD;
      carboplatin can make your tumor smaller or disappear, and for how long, compared with the&#xD;
      combination of docetaxel and carboplatin.&#xD;
&#xD;
      The effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or&#xD;
      docetaxel with carboplatin have on your disease related symptoms.&#xD;
&#xD;
      The relation of smoking history and hormone replacement therapy (for women only) may have to&#xD;
      your lung cancer treatment results.&#xD;
&#xD;
      The effects of certain genes and proteins in samples of your blood and tumor tissue in order&#xD;
      to learn more about NSCLC and how enzastaurin works in the body.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>Baseline to measured PD up to 22.3 months</time_frame>
    <description>Time to disease progression was defined as the time from randomization to the first date of documented disease progression or death if the participant dies due to disease progression. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions. For participants who have not had documented disease progression, time to disease progression was censored at the date of death or date of last visit. For participants who received other anti-tumor therapy prior to disease progression, time to disease progression was censored at the first available date of other anti-tumor therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Biomarkers Associated With Clinical Outcomes</measure>
    <time_frame>Baseline, Cycle 1, Cycle 2 (21-day cycle each), and 30-day post study treatment follow-up</time_frame>
    <description>As specified in the protocol, tumor biomarker samples were collected from participants on the pemetrexed arms only but were not intended to be analyzed at the individual study level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Smoking History (All Participants) and Hormone Replacement Therapy (Female Participants Only) Associated With Clinical Outcomes</measure>
    <time_frame>Baseline</time_frame>
    <description>Data for smoking history and hormone replacement therapy were collected but were not intended to be analyzed at the individual study level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) or Deaths</measure>
    <time_frame>Baseline through study completion up to 6 cycles (21-day cycle each) and 30-day safety follow-up</time_frame>
    <description>Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality, or deaths during the study including 30 days after treatment discontinuation. A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events section of this report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale</measure>
    <time_frame>Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]</time_frame>
    <description>The FACT-L version 4 scale is used to assess health-related quality of life (HRQoL) in participants with lung cancer. The FACT-L has 5 subscales: Physical Well-Being (PWB), Social and Family Well-Being (SFWB) and Functional Well-Being (FWB) subscales which include 7 items each, Emotional Well-Being (EWB) subscale which includes 6 items, and a Lung-Cancer Specific (LCS) subscale which include 7 items. Total FACT-L is the sum of all 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 equal to &quot;worst quality of life&quot; to 136 equal to &quot;best quality of life&quot;. The Least Square (LS) mean was calculated using an analysis of covariance (ANCOVA) model adjusted for change scores and baseline scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale</measure>
    <time_frame>Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]</time_frame>
    <description>The FACT-Taxane version 4 scale is used to assess HRQoL in participants receiving taxane chemotherapy. The FACT-taxane has 5 subscales: PWB, SFWB, and FWB subscales which include 7 items each, EWB subscale which includes 6 items, and a taxane subscale which include 16 items and has two domains (neurotoxicity and taxane). Total FACT-Taxane is the sum of all the 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 &quot;worst quality of life&quot; to 172 &quot;best quality of life&quot;. The LS mean was calculated using an ANCOVA model adjusted for change scores and baseline scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to date of death from any cause up to 35 months</time_frame>
    <description>OS was the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]</measure>
    <time_frame>Baseline to measured PD up to 22.3 months</time_frame>
    <description>Response was defined using RECIST, version 1.0 criteria. Participants with a best response of CR or PR were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR or PR (Duration of Response)</measure>
    <time_frame>Date of first response to the date of progression or death due to any cause up to 22.3 months</time_frame>
    <description>The duration of a CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of progression or death due to any cause. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-Treatment Failure (TTF)</measure>
    <time_frame>Baseline to stopping treatment up to 14.1 months</time_frame>
    <description>TTF was defined as the time from randomization to the first observation of PD, death due to any cause, or early discontinuation of treatment. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions. TTF was censored at the date of the last follow-up visit for participants who did not discontinue early, who were still alive, and who have not progressed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Enzastaurin/Pemetrexed/Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed/Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel/Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzastaurin</intervention_name>
    <description>1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression</description>
    <arm_group_label>Enzastaurin/Pemetrexed/Carboplatin</arm_group_label>
    <other_name>LY317615</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>500 milligrams per square meter (mg/m^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease</description>
    <arm_group_label>Enzastaurin/Pemetrexed/Carboplatin</arm_group_label>
    <arm_group_label>Pemetrexed/Carboplatin</arm_group_label>
    <other_name>LY231514</other_name>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>75 mg/m^2, IV, q 21 days, six 21 day cycles or progressive disease</description>
    <arm_group_label>Docetaxel/Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease</description>
    <arm_group_label>Docetaxel/Carboplatin</arm_group_label>
    <arm_group_label>Enzastaurin/Pemetrexed/Carboplatin</arm_group_label>
    <arm_group_label>Pemetrexed/Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  You must have been diagnosed with NSCLC.&#xD;
&#xD;
          -  You must be able to visit the doctor's office weekly during the active treatment&#xD;
             period and as needed during the study follow-up period.&#xD;
&#xD;
          -  You must be willing and able to swallow capsules.&#xD;
&#xD;
          -  Your entry labs and medical tests must meet study requirements.&#xD;
&#xD;
          -  You must be willing to have blood samples drawn and tissue samples obtained for gene&#xD;
             and protein testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  You have received radiation within 2 weeks of study enrollment.&#xD;
&#xD;
          -  You have previously received any anti-cancer drug therapy for NSCLC.&#xD;
&#xD;
          -  You have an active infection or other serious condition.&#xD;
&#xD;
          -  You take aspirin or aspirin-like medication regularly and are not able to stop taking&#xD;
             them for a few days during each cycle of chemotherapy.&#xD;
&#xD;
          -  You have recently lost a significant amount of weight.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2006</study_first_submitted>
  <study_first_submitted_qc>March 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2006</study_first_posted>
  <results_first_submitted>April 20, 2021</results_first_submitted>
  <results_first_submitted_qc>April 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <disposition_first_submitted>May 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>May 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 2, 2010</disposition_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Presented in the participant flow are the reasons participants discontinued from study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enzastaurin/Pemetrexed/Carboplatin</title>
          <description>Enzastaurin loading dose of 1125 milligrams (mg) or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 milligrams per square meter (mg/m^2) and carboplatin [area under the curve (AUC)] 6 milligrams*minutes per milliliter (mg*min/mL) as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
        <group group_id="P2">
          <title>Pemetrexed/Carboplatin</title>
          <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
        <group group_id="P3">
          <title>Docetaxel/Carboplatin</title>
          <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated Complication</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New Primary Disease Identified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Enzastaurin/Pemetrexed/Carboplatin</title>
          <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
        <group group_id="B2">
          <title>Pemetrexed/Carboplatin</title>
          <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
        <group group_id="B3">
          <title>Docetaxel/Carboplatin</title>
          <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="9.8"/>
                    <measurement group_id="B2" value="64.0" spread="10.0"/>
                    <measurement group_id="B3" value="64.0" spread="9.1"/>
                    <measurement group_id="B4" value="64.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Stage at Study Entry</title>
          <description>Disease stage describes how big the tumor is and how far it has spread from the site of origin. Stages range from Stage I to Stage IV. Stage III is further separated into Stage IIIA and IIIB. Stage IIIB (cancer spread to distant lymph nodes and invaded other organs like heart, esophagus etc). Stage IV (cancer spread throughout the body).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Stage IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Disease Progression</title>
        <description>Time to disease progression was defined as the time from randomization to the first date of documented disease progression or death if the participant dies due to disease progression. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions. For participants who have not had documented disease progression, time to disease progression was censored at the date of death or date of last visit. For participants who received other anti-tumor therapy prior to disease progression, time to disease progression was censored at the first available date of other anti-tumor therapy.</description>
        <time_frame>Baseline to measured PD up to 22.3 months</time_frame>
        <population>All randomized participants. Twenty (20) participants in Enzastaurin/Pemetrexed/Carboplatin group, 15 participants in Pemetrexed/Carboplatin group, and 17 participants in Docetaxel/Carboplatin group were censored for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Time to disease progression was defined as the time from randomization to the first date of documented disease progression or death if the participant dies due to disease progression. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions. For participants who have not had documented disease progression, time to disease progression was censored at the date of death or date of last visit. For participants who received other anti-tumor therapy prior to disease progression, time to disease progression was censored at the first available date of other anti-tumor therapy.</description>
          <population>All randomized participants. Twenty (20) participants in Enzastaurin/Pemetrexed/Carboplatin group, 15 participants in Pemetrexed/Carboplatin group, and 17 participants in Docetaxel/Carboplatin group were censored for analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="3.2" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4.6" upper_limit="6.5"/>
                    <measurement group_id="O3" value="4.1" lower_limit="2.6" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Biomarkers Associated With Clinical Outcomes</title>
        <description>As specified in the protocol, tumor biomarker samples were collected from participants on the pemetrexed arms only but were not intended to be analyzed at the individual study level.</description>
        <time_frame>Baseline, Cycle 1, Cycle 2 (21-day cycle each), and 30-day post study treatment follow-up</time_frame>
        <population>Zero participants were analyzed due to insufficient samples being collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Biomarkers Associated With Clinical Outcomes</title>
          <description>As specified in the protocol, tumor biomarker samples were collected from participants on the pemetrexed arms only but were not intended to be analyzed at the individual study level.</description>
          <population>Zero participants were analyzed due to insufficient samples being collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Smoking History (All Participants) and Hormone Replacement Therapy (Female Participants Only) Associated With Clinical Outcomes</title>
        <description>Data for smoking history and hormone replacement therapy were collected but were not intended to be analyzed at the individual study level.</description>
        <time_frame>Baseline</time_frame>
        <population>Zero participants were analyzed due to insufficient samples being collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Smoking History (All Participants) and Hormone Replacement Therapy (Female Participants Only) Associated With Clinical Outcomes</title>
          <description>Data for smoking history and hormone replacement therapy were collected but were not intended to be analyzed at the individual study level.</description>
          <population>Zero participants were analyzed due to insufficient samples being collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) or Deaths</title>
        <description>Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality, or deaths during the study including 30 days after treatment discontinuation. A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events section of this report.</description>
        <time_frame>Baseline through study completion up to 6 cycles (21-day cycle each) and 30-day safety follow-up</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) or Deaths</title>
          <description>Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality, or deaths during the study including 30 days after treatment discontinuation. A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events section of this report.</description>
          <population>Randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths Due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale</title>
        <description>The FACT-L version 4 scale is used to assess health-related quality of life (HRQoL) in participants with lung cancer. The FACT-L has 5 subscales: Physical Well-Being (PWB), Social and Family Well-Being (SFWB) and Functional Well-Being (FWB) subscales which include 7 items each, Emotional Well-Being (EWB) subscale which includes 6 items, and a Lung-Cancer Specific (LCS) subscale which include 7 items. Total FACT-L is the sum of all 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 equal to &quot;worst quality of life&quot; to 136 equal to &quot;best quality of life&quot;. The Least Square (LS) mean was calculated using an analysis of covariance (ANCOVA) model adjusted for change scores and baseline scores.</description>
        <time_frame>Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]</time_frame>
        <population>Randomized participants with non-missing FACT-L data both at baseline and at the specified cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale</title>
          <description>The FACT-L version 4 scale is used to assess health-related quality of life (HRQoL) in participants with lung cancer. The FACT-L has 5 subscales: Physical Well-Being (PWB), Social and Family Well-Being (SFWB) and Functional Well-Being (FWB) subscales which include 7 items each, Emotional Well-Being (EWB) subscale which includes 6 items, and a Lung-Cancer Specific (LCS) subscale which include 7 items. Total FACT-L is the sum of all 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 equal to &quot;worst quality of life&quot; to 136 equal to &quot;best quality of life&quot;. The Least Square (LS) mean was calculated using an analysis of covariance (ANCOVA) model adjusted for change scores and baseline scores.</description>
          <population>Randomized participants with non-missing FACT-L data both at baseline and at the specified cycle.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 (Week 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.98" spread="1.86"/>
                    <measurement group_id="O2" value="1.12" spread="1.78"/>
                    <measurement group_id="O3" value="-3.33" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 (Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="2.19"/>
                    <measurement group_id="O2" value="-1.54" spread="2.08"/>
                    <measurement group_id="O3" value="-2.16" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 (Week 9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="2.30"/>
                    <measurement group_id="O2" value="0.64" spread="2.25"/>
                    <measurement group_id="O3" value="-1.93" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="2.47"/>
                    <measurement group_id="O2" value="3.54" spread="2.23"/>
                    <measurement group_id="O3" value="-0.81" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 (Week 15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="2.95"/>
                    <measurement group_id="O2" value="-0.26" spread="2.57"/>
                    <measurement group_id="O3" value="-4.69" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 (Week 18)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.38" spread="3.54"/>
                    <measurement group_id="O2" value="-0.83" spread="2.84"/>
                    <measurement group_id="O3" value="3.38" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.96</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 1 (Week 3).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 1 (Week 3).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.92</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 2 (Week 6).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 2 (Week 6).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.71</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 3 (Week 9).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.66</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 3 (Week 9).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 4 (Week 12).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 4 (Week 12).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.19</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 5 (Week 15).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 5 (Week 15).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.63</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 6 (Week 18).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.55</p_value>
            <p_value_desc>P-value is for the change in Total FACT-L at Cycle 6 (Week 18).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale</title>
        <description>The FACT-Taxane version 4 scale is used to assess HRQoL in participants receiving taxane chemotherapy. The FACT-taxane has 5 subscales: PWB, SFWB, and FWB subscales which include 7 items each, EWB subscale which includes 6 items, and a taxane subscale which include 16 items and has two domains (neurotoxicity and taxane). Total FACT-Taxane is the sum of all the 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 &quot;worst quality of life&quot; to 172 &quot;best quality of life&quot;. The LS mean was calculated using an ANCOVA model adjusted for change scores and baseline scores.</description>
        <time_frame>Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]</time_frame>
        <population>Randomized participants with non-missing FACT-Taxane data both at baseline and at the specified cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale</title>
          <description>The FACT-Taxane version 4 scale is used to assess HRQoL in participants receiving taxane chemotherapy. The FACT-taxane has 5 subscales: PWB, SFWB, and FWB subscales which include 7 items each, EWB subscale which includes 6 items, and a taxane subscale which include 16 items and has two domains (neurotoxicity and taxane). Total FACT-Taxane is the sum of all the 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 &quot;worst quality of life&quot; to 172 &quot;best quality of life&quot;. The LS mean was calculated using an ANCOVA model adjusted for change scores and baseline scores.</description>
          <population>Randomized participants with non-missing FACT-Taxane data both at baseline and at the specified cycle.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 (Week 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.16" spread="2.20"/>
                    <measurement group_id="O2" value="-0.78" spread="2.08"/>
                    <measurement group_id="O3" value="-2.17" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 (Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.22" spread="2.90"/>
                    <measurement group_id="O2" value="-5.66" spread="2.76"/>
                    <measurement group_id="O3" value="-3.13" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 (Week 9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="3.35"/>
                    <measurement group_id="O2" value="-1.52" spread="3.32"/>
                    <measurement group_id="O3" value="-4.40" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="3.65"/>
                    <measurement group_id="O2" value="-0.77" spread="3.29"/>
                    <measurement group_id="O3" value="-2.58" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 (Week 15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" spread="3.71"/>
                    <measurement group_id="O2" value="-3.11" spread="3.24"/>
                    <measurement group_id="O3" value="-7.74" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 (Week 18)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="3.93"/>
                    <measurement group_id="O2" value="-2.81" spread="3.26"/>
                    <measurement group_id="O3" value="-0.34" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 1 (Week 3).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 1 (Week 3).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.69</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 2 (Week 6).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.77</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 2 (Week 6).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.83</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 3 (Week 9).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.78</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 3 (Week 9).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 4 (Week 12).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.91</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 4 (Week 12).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 5 (Week 15).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.53</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 5 (Week 15).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.80</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 6 (Week 18).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>P-value is for the change in Total FACT-Taxane at Cycle 6 (Week 18).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.</description>
        <time_frame>Baseline to date of death from any cause up to 35 months</time_frame>
        <population>All randomized participants. Sixteen (16) participants in Enzastaurin/Pemetrexed/Carboplatin group, 20 participants in Pemetrexed/Carboplatin group, and 19 participants in Docetaxel/Carboplatin group were censored for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.</description>
          <population>All randomized participants. Sixteen (16) participants in Enzastaurin/Pemetrexed/Carboplatin group, 20 participants in Pemetrexed/Carboplatin group, and 19 participants in Docetaxel/Carboplatin group were censored for analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="5.7" upper_limit="11.2"/>
                    <measurement group_id="O2" value="12.7" lower_limit="9.3" upper_limit="17.0"/>
                    <measurement group_id="O3" value="9.2" lower_limit="5.9" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]</title>
        <description>Response was defined using RECIST, version 1.0 criteria. Participants with a best response of CR or PR were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.</description>
        <time_frame>Baseline to measured PD up to 22.3 months</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]</title>
          <description>Response was defined using RECIST, version 1.0 criteria. Participants with a best response of CR or PR were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of CR or PR (Duration of Response)</title>
        <description>The duration of a CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of progression or death due to any cause. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.</description>
        <time_frame>Date of first response to the date of progression or death due to any cause up to 22.3 months</time_frame>
        <population>All randomized participants. 63 participants in Enzastaurin/Pemetrexed/Carboplatin group, 58 participants in Pemetrexed/Carboplatin group, and 53 participants in Docetaxel/Carboplatin group were censored for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg on Day -7 (pre-chemotherapy) followed by 500 mg administered once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of CR or PR (Duration of Response)</title>
          <description>The duration of a CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of progression or death due to any cause. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.</description>
          <population>All randomized participants. 63 participants in Enzastaurin/Pemetrexed/Carboplatin group, 58 participants in Pemetrexed/Carboplatin group, and 53 participants in Docetaxel/Carboplatin group were censored for analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="3.7" upper_limit="8.8"/>
                    <measurement group_id="O2" value="9.3" lower_limit="5.7" upper_limit="14.8"/>
                    <measurement group_id="O3" value="5.8" lower_limit="3.3" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-Treatment Failure (TTF)</title>
        <description>TTF was defined as the time from randomization to the first observation of PD, death due to any cause, or early discontinuation of treatment. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions. TTF was censored at the date of the last follow-up visit for participants who did not discontinue early, who were still alive, and who have not progressed.</description>
        <time_frame>Baseline to stopping treatment up to 14.1 months</time_frame>
        <population>All randomized participants. Thirty four (34) participants in Pemetrexed/Carboplatin group and 23 participants in Docetaxel/Carboplatin group were censored for analysis. No participants were censored in Enzastaurin/Pemetrexed/Carboplatin group.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzastaurin/Pemetrexed/Carboplatin</title>
            <description>Enzastaurin loading dose of 1125 mg or 1200 mg orally on Day -7 (pre-chemotherapy) followed by 500 mg administered orally once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed/Carboplatin</title>
            <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel/Carboplatin</title>
            <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-Treatment Failure (TTF)</title>
          <description>TTF was defined as the time from randomization to the first observation of PD, death due to any cause, or early discontinuation of treatment. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions. TTF was censored at the date of the last follow-up visit for participants who did not discontinue early, who were still alive, and who have not progressed.</description>
          <population>All randomized participants. Thirty four (34) participants in Pemetrexed/Carboplatin group and 23 participants in Docetaxel/Carboplatin group were censored for analysis. No participants were censored in Enzastaurin/Pemetrexed/Carboplatin group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.7" upper_limit="3.7"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.8" upper_limit="5.1"/>
                    <measurement group_id="O3" value="2.6" lower_limit="1.3" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Study-specific clinical outcomes due to PD were not considered to be a SAE unless the investigator deemed it related to the use of the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Enzastaurin/Pemetrexed/Carboplatin</title>
          <description>Enzastaurin loading dose of 1125 mg or 1200 mg on Day -7 (pre-chemotherapy) followed by 500 mg administered once daily starting from Day -6 until disease progression.&#xD;
Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
        <group group_id="E2">
          <title>Pemetrexed/Carboplatin</title>
          <description>Pemetrexed 500 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
        <group group_id="E3">
          <title>Docetaxel/Carboplatin</title>
          <description>Docetaxel 75 mg/m^2 and carboplatin AUC 6 mg*min/mL as an intravenous infusion on Day 1 every 21 days for a maximum of 6 cycles (21-day cycle) or disease progression whichever came first.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Oedema due to cardiac disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Platelet count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>White blood cell count</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="15" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="67"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="72"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="18" subjects_at_risk="67"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E3" events="23" subjects_affected="19" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="57" subjects_affected="34" subjects_at_risk="67"/>
                <counts group_id="E2" events="52" subjects_affected="32" subjects_at_risk="72"/>
                <counts group_id="E3" events="40" subjects_affected="24" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="72"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="67"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="72"/>
                <counts group_id="E3" events="19" subjects_affected="15" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="46" subjects_affected="28" subjects_at_risk="67"/>
                <counts group_id="E2" events="55" subjects_affected="39" subjects_at_risk="72"/>
                <counts group_id="E3" events="63" subjects_affected="35" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="11" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" events="99" subjects_affected="40" subjects_at_risk="67"/>
                <counts group_id="E2" events="132" subjects_affected="53" subjects_at_risk="72"/>
                <counts group_id="E3" events="59" subjects_affected="34" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" events="88" subjects_affected="33" subjects_at_risk="67"/>
                <counts group_id="E2" events="114" subjects_affected="37" subjects_at_risk="72"/>
                <counts group_id="E3" events="138" subjects_affected="46" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Platelet count</sub_title>
                <counts group_id="E1" events="116" subjects_affected="37" subjects_at_risk="67"/>
                <counts group_id="E2" events="151" subjects_affected="43" subjects_at_risk="72"/>
                <counts group_id="E3" events="41" subjects_affected="18" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>White blood cell count</sub_title>
                <counts group_id="E1" events="63" subjects_affected="23" subjects_at_risk="67"/>
                <counts group_id="E2" events="99" subjects_affected="29" subjects_at_risk="72"/>
                <counts group_id="E3" events="65" subjects_affected="21" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E3" events="27" subjects_affected="19" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="32" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="72"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

